Details of the Drug

General Information of Drug (ID: DM19Y0T)

Drug Name

SUPER-LEU-DOX

Synonyms

CPI-0004; CPI-0004Na; CPI-004Na; DTS-201; TAP-doxorubicin; TSP-doxorubicin; Phthacene-5,12-dione sodium salt; N-[N-(3-Carboxypropionyl)-beta-alanyl-L-leucyl-L-alanyl-L-leucyl]daunorubicin sodium salt; (8S,10S)-10-[3-[N-(3-Carboxy-1-oxopropyl)-beta-alanyl-L-leucyl-L-alanyl-L-leucylamido]-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy]-8-(hydroxyacetyl)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrona

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[1]
------------------------------------------------------------------------------------

Cross-matching ID

DrugBank ID: DB06071
TTD ID: D0T3CE

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN ; TOP2B_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009260)
2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.